Head-To-Head Contrast: RenovaCare (OTCMKTS:RCAR) versus Embecta (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) and RenovaCare (OTCMKTS:RCAR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Embecta and RenovaCare, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	1	0	0	0	1.00
RenovaCare	0	0	0	0	0.00

Embecta presently has a consensus target price of $12.00, suggesting a potential downside of 13.17%. Given RenovaCare’s higher possible upside, analysts plainly believe RenovaCare is more favorable than Embecta.

Profitability

This table compares Embecta and RenovaCare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Embecta	6.23%	-19.09%	12.27%
RenovaCare	N/A	N/A	N/A

Insider & Institutional Ownership

93.8% of Embecta shares are owned by institutional investors. 0.3% of Embecta shares are owned by insiders. Comparatively, 0.9% of RenovaCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Embecta and RenovaCare”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.12 billion	0.71	$70.40 million	$1.20	11.52
RenovaCare	N/A	N/A	-$4.47 million	N/A	N/A

Embecta has higher revenue and earnings than RenovaCare.

Risk and Volatility

Embecta has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, RenovaCare has a beta of -99.76, suggesting that its stock price is 10,076% less volatile than the S&P 500.

Summary

Embecta beats RenovaCare on 7 of the 10 factors compared between the two stocks.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

About RenovaCare

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.